Too much, too soon?

摘要

We read with interest the article by Chid et al. on the use of granulocyte colony stimulating factor (G-CSF) in the treatment of amyotrophic lateral sclerosis (ALS). ALS is a devastating disease with a significant clinical and caregiver burden. The only FDA-approved treatment, riluzole, increases the life expectancy by a couple of months. New therapies would be welcomed by clinicians, patients, and caregivers alike. In our enthusiasm to welcome new therapies, however, we must be extremely cautious of their potential adverse effects.